Submit a utility to the registry.

Filter results using search terms, or by selecting one or more valuation, condition, or population.

Viewing 1 - 10 of 44 results
Title   Year(s) of data collection   Valuation Method   Country   Condition  
Selection of autoimmune disease health state utilities (He A, Spelman T et al., J Neurol Neurosurg Psychiatry. 2023. doi:10.1136/jnnp-2022-330169) 2001 - 2020 EQ-5D-3L Sweden Multiple sclerosis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
690 adults with relapsing multiple sclerosis in a Swedish registry to examine the association between early treatment of multiple sclerosis and patient-reported outcomes
Title
Selection of autoimmune disease health state utilities (Armuzzi A et al., BMC Gastroenterol. 2023. doi:10.1186/s12876-023-02640-7)
Year(s) of data collection
2020 - 2021
Valuation Method
EQ-5D-5L
Country
France, Germany, Italy, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America
Condition
Ulcerative colitis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
a point-in-time survey of 164 matched patients treated with tofacitinib
Title
Selection of autoimmune disease health state utilities (Saccà F et al., J Neurol. 2023. doi:10.1007/s00415-022-11517-w)
Year(s) of data collection
2018 - 2020
Valuation Method
EQ-5D-5L
Country
Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom of Great Britain and Northern Ireland, United States of America
Condition
Myasthenia gravis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
167 participants in phase 3 RCT of efgartigimod, ADAPT trial
Title
Selection of autoimmune disease health state utilities (Mitsikostas DD et al., Adv Ther. 2023. doi:10.1007/s12325-022-02388-8)
Year(s) of data collection
2012 - 2016
Valuation Method
EQ-5D-3L
Country
Greece
Condition
Multiple sclerosis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
A prospective observational study of 458 participants under treatment with fingolimod conducted by hospital-based and private practice neurologists
Title
Selection of autoimmune disease health state utilities (Schreiber S et al., J Crohns Colitis. 2023. doi:10.1093/ecco-jcc/jjad018)
Year(s) of data collection
2017 - 2018
Valuation Method
EQ-5D
Country
Argentina, Australia, Belgium, Bulgaria, Canada, Croatia, Czechia, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea (Republic of), Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan (Province of China), Ukraine, United Kingdom of Great Britain and Northern Ireland, United States of America
Condition
Ulcerative colitis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
An RCT for filgotinib in 786 adults with moderately to severely active UC
Title
Selection of autoimmune disease health state utilities (Chung MP et al., Rheumatology (Oxford). 2022. doi:10.1093/rheumatology/keab810)
Year(s) of data collection
2016 - 2020
Valuation Method
SF-6D
Country
United States of America
Condition
Calcinosis in systemic sclerosis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
12 participants from a prospective, single-arm, open-label, dose-escalation trial
Title
Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)
Year(s) of data collection
2021
Valuation Method
EQ-5D-5L, HUI3
Country
Belgium, Canada, Denmark, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America
Condition
Myasthenia gravis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
9000 participants in the general population norms study that included adult patients with gMG randomly assigned to treatment with efgartigimod or conventional therapy
Title
Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)
Year(s) of data collection
2019 - 2022
Valuation Method
EQ-5D-5L, HUI3
Country
Canada, Denmark, France, Germany, Italy, Japan, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America
Condition
Myasthenia gravis
DOI
10.7910/DVN/XTLOGB
Author(s)
Registry, Utilities
Description
Health state utilities for autoimmune disease conditions
Sample Characteristics
1299 participants (EQ-5D-5L) and 549 participants (HUI3) from MyRealWorld-MG study
Title
Selection of COVID-19 health state utilities (Chakravarty R et al., Indian J Psychol Med. 2023. doi:10.1177/02537176221140557)
Year(s) of data collection
2021
Valuation Method
EQ-5D-5L
Country
India
Condition
COVID-19
DOI
10.7910/DVN/MJ4J77
Author(s)
Registry, Utilities
Description
Health state utilities for states related to COVID-19
Sample Characteristics
80 COVID-19 patients treated with single infusion tocilizumab or no treatment
Title
Selection of COVID-19 health state utilities (Huarcaya-Victoria J et al., Qual Life Res. 2023. doi:10.1007/s11136-022-03208-w)
Year(s) of data collection
2020
Valuation Method
EQ-5D-5L
Country
Peru
Condition
COVID-19
DOI
10.7910/DVN/MJ4J77
Author(s)
Registry, Utilities
Description
Health state utilities for states related to COVID-19
Sample Characteristics
prospective sample of 119 hospitalized patients who survived COVID-19 at 3 and 13 months after discharge